Skip to main content

Table 2 Treatment recommendations and hospitalization policies for imported, uncomplicated falciparum malaria in selected European countries

From: Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre study

  First-line Hospitalization policy
treatment Recommendations (R) or standard practice (SP)
Belgium Atovaquone-proguanilArtemether-lumefantrine SP : hospitalization (ambulatory treatment possible under certain conditions)
  Quinine + cycline  
France Atovaquone-proguanil Artemether-lumefantrine R : Ambulatory treatment possible on the basis of specific clinical and biological parameters
Germany Atovaquone-proguanil Artemether-lumefantrine R : hospitalization recommended until treatment completed and patient parasite-free
  Mefloquine  
Italy Atovaquone-proguanil SP : hospitalization (ambulatory treatment possible under certain conditions)
  Mefloquine  
Spain Quinine + cycline or clindamycin Atovaquone-proguanil SP: hospitalization (ambulatory treatment possible under certain conditions)
Switzerland Artemether-lumefantrine Atovaquone-proguanil SP: hospitalization (ambulatory treatment possible under certain conditions)
United Kingdom Atovaquone-proguanil R : Systematically, at least 24 h
  Artemether-lumefantrine  
  Quinine + cyclines  
The Netherlands Atovaquone-proguanil Artemether-lumefantrine SP: hospitalization (ambulatory treatment possible under certain conditions)
  Quinine + cyclines  
  Chloroquine*  
  1. *selected areas with known chloroquine-sensitive P. falciparum, e.g. Central America.